Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Semaglutide, Tirzepatide, Metformin.
- Who it may be relevant to
- Registry conditions: Adults With Simple Obesity. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
Overview
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
Interventions
- Drug Semaglutide
Semaglutide administered once weekly by subcutaneous injection.Dose titrated from 0.25 mg to 2.0 mg as tolerated over 24 weeks - Drug Tirzepatide
Tirzepatide administered once weekly by subcutaneous injection. Dose titrated from 2.5 mg to 10 mg as tolerated over 24 weeks - Drug Metformin
Metformin administered orally. Dose titrated from 500 mg to 1500-2000 mg daily, based on tolerance, for 24 weeks
Primary outcome measures
- Change in DNA methylation-based biological age measured by iWatchAge [Time frame: Baseline and Week 24]
Eligibility criteria
Inclusion criteria
- Adults aged 18 to 75 years.
- Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m².
- Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months.
- Able and willing to comply with study procedures and complete follow-up assessments.
- Provide written informed consent.
Exclusion criteria
- Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism).
- Use of anti-obesity medications or participation in another weight-loss program within the past 3 months.
- Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy.
- History of pancreatitis, severe gastrointestinal disease, or bariatric surgery.
- Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation.
- Pregnant or breastfeeding women, or women planning pregnancy during the study period.
- Current participation in any other clinical trial.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- The Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou
Identifiers
NCT: NCT07293325 · 2025-0568